Annovera™

FDA Approval Conference Call

August 13, 2018
Forward-Looking Statements

This presentation by TherapeuticsMD, Inc. (referred to as “we” and “our”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of our managerial experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate.

Forward-looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which may be outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as our current reports on Form 8-K, and include the following: whether the FDA will approve the NDA for our TX-001HR product candidate and whether such approval will occur by the PDUFA target action date; our ability to maintain or increase sales of our products; our ability to develop and commercialize our hormone therapy drug candidates and one-year contraceptive vaginal system licensed product and obtain additional financing necessary therefor; whether we will be able to comply with the covenants and conditions under our term loan agreement; the length, cost and uncertain results of our clinical trials; potential of adverse side effects or other safety risks that could preclude the approval of our hormone therapy drug candidates or adversely affect the commercialization of our current or future approved products; the ability of our licensees to commercialize and distribute our product and product candidates; our reliance on third parties to conduct our clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of our common stock; and the concentration of power in our stock ownership.

TX-001HR, TX-005HR, and TX-006HR are investigational drugs and are not approved by the FDA. This non-promotional presentation is intended for investor audiences only.
Annovera - 1-Year Vaginal System
Segesterone Acetate [Nestorone® (NES)]/Ethinyl Estradiol (EE)

First and only **patient-controlled, procedure-free, long-acting, reversible** birth control

- Product fits into existing TXMD infrastructure
  - **Approved: August 10, 2018**
  - Segesterone acetate component of Annovera expected to be classified as NCE with 5 year exclusivity

- Developed by the Population Council – developer of multi-billion dollar products
  - ParaGard® and Mirena® IUDs; Norplant® and Jadelle® implants; and Progering®
  - Funded by several organizations, including: Bill & Melinda Gates Foundation, US National Institutes of Health, USAID and The Population Council

- The ring system is composed of a “squishy” silicone elastomer
  - 21/7 days cyclical dosing regimen
  - 89% overall patient satisfaction in clinical trials

- Average daily release over one year of use:
  - 0.15 mg/day segesterone acetate
  - 0.013 mg/day ethinyl estradiol

- Nestorone: progesterone derived unique progestin
  - High progestational potency and antiovulatory activity
  - No androgenic, estrogenic or glucocorticoid effects at contraceptive doses

---

Clinical Trial Experience

Efficacy & Safety\(^1,2\)

- **Based on two pivotal Phase 3 clinical trials with 2,308 women**
  - Efficacy and safety consistent with other birth control pills, patches and hormonal rings

**Efficacy**

- 97.3% effective in preventing pregnancy when used as directed
  - Primary Endpoint Pearl Index was 2.98 per 100 woman-years
  - Consistent with all other combination hormone birth control pills, patches and other rings

**Safety**

- Class labeling for combination hormonal contraceptives (CHCs)
- All CHCs carry the boxed warning about cigarette smoking and serious cardiovascular events, particularly for women over age 35
- The risk profile is consistent with other CHCs
- The most common adverse reactions include headache, nausea/vomiting, vulvovaginal mycotic infections, abdominal pain, dysmenorrhea, vaginal discharge, UTIs, among others
- Consistent with other CHC products the most common adverse reactions leading to discontinuation were:
  - Irregular bleeding (1.7%), headache (1.3%), vaginal discharge (1.3%), and nausea/vomiting (1.2%)

\(^1\) [www.annovera.pi.pdf](http://www.annovera.pi.pdf)
\(^2\) Data with respect to the Phase 3 clinical trials
Phase 3 Acceptability Study
Demonstrated 1-Year Contraceptive Vaginal System High User Satisfaction

Acceptability Data

- Phase 3 acceptability study (n=905 subjects)
- Overall satisfaction 89% related to ease of use, side effects, expulsions/feeling the product, and physical effect during sexual activity
- High rates of adherence and continuation

<table>
<thead>
<tr>
<th>Ease of inserting (N=905)</th>
<th>Ease of removing (N=905)</th>
<th>Ease of remembering CVR insertion (N=905)</th>
<th>Ease of remembering CVR removal (N=905)</th>
<th>No side effects reported on questionnaire (N=905)</th>
</tr>
</thead>
<tbody>
<tr>
<td>90.8% (n=823)</td>
<td>88.2% (n=798)</td>
<td>87.6% (n=793)</td>
<td>85.2% (n=771)</td>
<td>81.8% (n=740)</td>
</tr>
</tbody>
</table>


**Annovera Deal Terms**

### Milestone Payments
- Upon FDA approval: $20mm
- First commercial batch release: $20mm
- $200mm in cumulative net sales: $40mm
- $400mm in cumulative net sales: $40mm
- $1b in cumulative net sales: $40mm

### Royalty %
- **Step structure:**
  - Annual net sales ≤ $50mm: 5%
  - Annual net sales > $50mm and ≤ $150mm: 10%
  - Annual net sales > $150mm: 15%

### Additional Cost Considerations
- TXMD and Population Council jointly responsible for one observational PMR study*

---

*Costs exceeding $20mm to be shared with Population Council*
NuvaRing – Large Established Ring Market

- NuvaRing Owner: Merck
- $500mm+ net sales in US ring market with no other branded products in the space*
- NuvaRing monthly contraceptive ring (vs. Annovera 1-year ring)
  - Annual WAC Price of $2,013 (vs. $1,400)
  - Semi-rigid ring body (vs. pliable/squishy)
  - Monthly visit to pharmacy (vs. one annual visit)
- 2 NuvaRing generics expected in 2019

*(Symphony Health Solutions PHAST Data powered by IDV. Net sales as reported in company filings.)

<table>
<thead>
<tr>
<th></th>
<th>Year End December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td>NuvaRing Net Revenue*</td>
<td>$426</td>
</tr>
<tr>
<td>market growth</td>
<td>8.2%</td>
</tr>
<tr>
<td>NuvaRing Scripts*</td>
<td>4.7</td>
</tr>
<tr>
<td>script growth</td>
<td>-1.4%</td>
</tr>
</tbody>
</table>
U.S. Prescription Contraceptive Market

- One of the largest therapeutic categories by script count
- ~ 90mm scripts\(^1\)
- ~ $5B U.S. net sales\(^2\)
- ~ 43 million women are at risk of unintended pregnancy of which ~ 18 million want to avoid pregnancy\(^3\)

**Daily Oral Contraceptives**
- OC’s continue to lose market share to longer acting solutions such as IUDs, Implants and Rings

**Long Acting Reversible Contraceptives**
- IUDs and Implants are experiencing significant growth as the market shifts towards long-acting solutions

---

\(^1\) IQVIA Total Patient Tracker database; Annual 2017


\(^3\) Contraceptive Use in the United States, Guttmacher, July 2018.
Expected Benefits of 1-Year Vaginal Contraceptive System

**Patients**

- Long-acting reversible birth control that doesn’t require a procedure or repeat doctor’s visit
- Softer and more pliable than NuvaRing and doesn’t require refrigeration
- “Vaginal System” - a new class of contraception with potential for $0 co-pay
- Acceptable for all indicated women including nulliparous women and women who are not in a monogamous relationship*
- Empowers women to be in complete control of their fertility and menstruation
- Available with a single annual pharmacy visit

**Healthcare Providers**

- A long-acting reversible birth control option that doesn’t require a procedure
- No requirement to buy, hold and manage inventory
- Acceptable for nulliparous women and women not in a monogamous relationship*
- Satisfies patients’ desire to be in control of their fertility and menstruation

*Lohr, et al. Use of intrauterine devices in nulliparous women. Contraception 95 (2017); 529-537
Unique Product Characteristics Should Lead to Good Payor Coverage

- Anticipate parity or discount pricing level ~$1400 annual WAC cost
  - 40% decrease to annual WAC of NuvaRing, reflects TXMD’s responsible brand pricing
  - Allows for improved patient adherence and a potential decrease in unplanned pregnancies
  - Only one pharmacy fill fee per year (estimated savings of $33 annually)
  - No repeat office visit or procedure fees (several hundred dollars)
  - Contains ethinyl estradiol and Nestorone®, a new and unique progestin
  - “Vaginal System”- a new class of contraception with potential for $0 co-pay

The Affordable Care Act (ACA) mandates that private health plans provide coverage for one treatment per class of contraception used by women with no patient out-of-pocket costs
TXMD Sales Force Has Strong Overlap With NuvaRing Prescribers

NuvaRing Prescribers Overlap with TXMD Sales Force¹

- 81% of total prescribers within current 150 TXMD territories
- No additional sales representatives needed

¹ IQUVIA Data
Commercialization Strategy & Timing

Focused Launch Strategy - Base Case Market Opportunity

- NuvaRing customers – monthly ring replaced by annual ring
- ~60K annual vitaMedMD prenatal customers who may proceed to contraception
- Patients who prefer long acting reversible contraception but fear procedures
- Healthcare providers who prefer long acting reversible contraception but forgo due to procedures and cost of procurement
- Nulliparous women and those who are not in a monogamous relationship who desire long acting reversible contraception but discouraged from IUDs

Commercialization & Launch Timing

- Estimated to be commercially available as early as Q3’19 with commercial launch as early as Q4’19 to Q1’20
- Additional marketing team exclusively focused on Annovera anticipated
- TXMD to be responsible for all aspects of promotion, product positioning, pricing, education programs, publications, sales messages, and any additional desired clinical studies (subject to oversight by the Joint Product Committee)

1. Lohr, et al. Use of intrauterine devices in nulliparous women. Contraception 95 (2017); 529-537
Contraceptive Pipeline

<table>
<thead>
<tr>
<th>Pre-Clinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>PDUFA Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-Year Vaginal Contraceptive System (NES/EE)</td>
<td></td>
<td></td>
<td></td>
<td>08/17/2018</td>
</tr>
<tr>
<td>3-Month Contraceptive Vaginal Ring (NES/E2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Next Generation 1-Year Vaginal Contraceptive System (NES/EE)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Exclusive rights to negotiate co-development and marketing rights

- 3 month ring using NES plus bio-identical Estradiol (E2) (Phase 2)
- 1 Year ring (NES/EE) life cycle management

1. TXMD has the option to co-develop and market in the US, if approved
Annovera™

Vasomotor symptoms affect up to 75% of perimenopausal women¹

TX-001HR®

Vulvar & Vaginal Atrophy

~60,000 New Prenatal Patients Many will go on contraception after breastfeeding

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539866/

*Investigational product, pending FDA approval

¹. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539866/